Businesses that are solid enough to perform well over extended periods, while consistently raising their payouts, are precisely what income investors should gravitate toward. Here are two corporations ...

Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Co. (DIS), Gilead Sciences ...

In the hunt for a remedy, when the baton is passed from dedicated academic scientists to an innovative company to trusted community advocates, outcomes for society can be especially powerful.

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in ...

Gilead Sciences Inc. has divulged bridged tricyclic carbamoylpyridone prodrugs acting as HIV integrase inhibitors reported to be useful for the treatment of HIV infection.

After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

On April 29, 2025, the U.S. Attorney’s Office for the Southern District of New York (SDNY) announced a $202 million civil False Claims Act ...

Gilead to Pay $202 Million to Settle DOJ Claims Over Speaker Program Kickbacks - Gilead Sciences, Inc. has agreed to pay $202 ...

Here are 10 recent healthcare industry lawsuits, settlements and legal developments that Becker's has reported since April 22: ...

Gilead Sciences has agreed to pay $202 million to resolve allegations that it violated the Anti-Kickback Statute by using speaker programs to incentivize physicians to prescribe HIV medications.

Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has partnered with Emory University in Atlanta to launch A ...